AR104984A1 - SELECTIVE COMPOUNDS FOR PYY AND ITS USES - Google Patents
SELECTIVE COMPOUNDS FOR PYY AND ITS USESInfo
- Publication number
- AR104984A1 AR104984A1 ARP160101755A ARP160101755A AR104984A1 AR 104984 A1 AR104984 A1 AR 104984A1 AR P160101755 A ARP160101755 A AR P160101755A AR P160101755 A ARP160101755 A AR P160101755A AR 104984 A1 AR104984 A1 AR 104984A1
- Authority
- AR
- Argentina
- Prior art keywords
- pyy
- compounds
- application
- selective compounds
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
Abstract
La solicitud hace referencia a compuestos para PYY con las modificaciones de aminoácidos 7Lys, 30Trp y 31Leu y además 22Ile o 28Tyr, y sus derivados. El compuesto de la solicitud corresponde a agonistas del receptor Y2 selectivo. La solicitud también hace referencia a composiciones farmacéuticas que comprenden dichos compuestos para PYY y excipientes farmacéuticamente aceptables, como también al uso médico de los compuestos para PYY.The application refers to compounds for PYY with the amino acid modifications 7Lys, 30Trp and 31Leu and also 22Ile or 28Tyr, and their derivatives. The compound of the application corresponds to selective Y2 receptor agonists. The application also refers to pharmaceutical compositions comprising said compounds for PYY and pharmaceutically acceptable excipients, as well as to the medical use of the compounds for PYY.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15171785 | 2015-06-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR104984A1 true AR104984A1 (en) | 2017-08-30 |
Family
ID=53404384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160101755A AR104984A1 (en) | 2015-06-12 | 2016-06-13 | SELECTIVE COMPOUNDS FOR PYY AND ITS USES |
Country Status (18)
Country | Link |
---|---|
US (1) | US10005824B2 (en) |
EP (1) | EP3307768A1 (en) |
JP (1) | JP6731958B2 (en) |
KR (1) | KR102476550B1 (en) |
CN (1) | CN107849110B (en) |
AR (1) | AR104984A1 (en) |
AU (1) | AU2016275735B2 (en) |
BR (1) | BR112017025108A2 (en) |
CA (1) | CA2988500A1 (en) |
IL (1) | IL255781B (en) |
MA (1) | MA43205A (en) |
MX (1) | MX2017015105A (en) |
MY (1) | MY187047A (en) |
RU (1) | RU2726777C2 (en) |
SA (1) | SA517390445B1 (en) |
TW (1) | TWI694082B (en) |
WO (1) | WO2016198682A1 (en) |
ZA (1) | ZA201707782B (en) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013014942B1 (en) | 2010-12-16 | 2020-01-28 | Novo Nordisk As | solid compositions for administration, and their uses |
KR102072202B1 (en) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Compositions of glp-1 peptides and preparation thereof |
MX369818B (en) | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Selective pyy compounds and uses thereof. |
WO2015071356A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
US11229229B2 (en) | 2016-06-14 | 2022-01-25 | Purecircle Usa Inc. | Steviol glycosides compositions, production methods and uses |
PL3746111T3 (en) | 2018-02-02 | 2024-01-15 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
TWI749381B (en) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | Protein tyrosine-tyrosine analogs and methods of using the same |
CN116726361A (en) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | Methods and devices for treating diseases with biologic therapeutic agents |
WO2021023817A1 (en) * | 2019-08-07 | 2021-02-11 | Novo Nordisk A/S | Solid composition comprising a pyy compound and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
WO2022029231A1 (en) | 2020-08-07 | 2022-02-10 | Boehringer Ingelheim International Gmbh | Soluble npy2 receptor agonists |
CN116710462A (en) | 2021-01-20 | 2023-09-05 | 维京治疗公司 | Compositions and methods for treating metabolic disorders and liver diseases |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299052A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and a permeation enhancer |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
WO2024038067A1 (en) | 2022-08-18 | 2024-02-22 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR960701653A (en) | 1993-03-29 | 1996-03-28 | 발라수브라마니암 엠비카이파칸 | Analogs of Peptide YY and Uses thereof |
US5574010A (en) | 1994-11-14 | 1996-11-12 | The Regents Of The University Of California | Treatment of pancreatic tumors with peptide YY and analogs thereof |
AU1159897A (en) | 1996-11-13 | 1998-06-03 | University Of Cincinnati, The | Analogs of peptide yy and uses thereof |
EP0908515A3 (en) | 1997-09-16 | 2000-04-26 | Smithkline Beecham Plc | Pancreatic polypeptide |
US6046167A (en) | 1998-03-25 | 2000-04-04 | University Of Cincinnati | Peptide YY analogs |
EP1086078B1 (en) | 1998-06-08 | 2003-02-05 | Schering Corporation | Neuropeptide y5 receptor antagonists |
US7601691B2 (en) | 1999-05-17 | 2009-10-13 | Conjuchem Biotechnologies Inc. | Anti-obesity agents |
BR0116206A (en) * | 2000-12-14 | 2003-12-23 | Amylin Pharmaceuticals Inc | Yy Peptide and yy Peptide Agonists for Treatment of Metabolic Disorders |
US6589938B2 (en) | 2001-06-29 | 2003-07-08 | National University Of Singapore | Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders |
EP2050460A1 (en) | 2001-09-24 | 2009-04-22 | Imperial Innovations Limited | PYY and agonists thereof for modification of feeding behaviour |
US8058233B2 (en) * | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
EP1583549A4 (en) | 2003-01-17 | 2006-10-04 | Sod Conseils Rech Applic | Peptide yy analogs |
US7572581B2 (en) | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
TW200522976A (en) | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
CN100444898C (en) | 2003-09-19 | 2008-12-24 | 诺沃挪第克公司 | Novel glp-1 derivatives |
BRPI0417684A (en) | 2003-12-18 | 2007-03-20 | Novo Nordisk As | compound, pharmaceutical composition, and use of a compound |
WO2005077072A2 (en) | 2004-02-11 | 2005-08-25 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
JP5638177B2 (en) | 2004-02-11 | 2014-12-10 | アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc | Pancreatic polypeptide family motif and polypeptide containing the motif |
CN100425282C (en) | 2004-03-17 | 2008-10-15 | 7Tm制药联合股份有限公司 | Y2/Y4 selective receptor agonists for therapeutic interventions |
EP1807099A2 (en) | 2004-03-17 | 2007-07-18 | 7TM Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
EP2057996A3 (en) | 2004-03-17 | 2009-11-04 | 7TM Pharma A/S | Y4 selective receptor agonists for therapeutic intervention |
BRPI0508861A (en) * | 2004-03-17 | 2007-08-28 | 7Tm Pharmas As | selective y2 / y4 receptor agonists for therapeutic interventions |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
WO2006005667A2 (en) | 2004-07-08 | 2006-01-19 | Novo Nordisk A/S | Polypeptide protracting tags comprising a tetrazole moiety |
WO2006020207A2 (en) | 2004-07-19 | 2006-02-23 | University Of Cincinnati | Compounds for control of appetite |
NZ553149A (en) * | 2004-08-12 | 2010-01-29 | Quest Pharmaceutical Services | Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions |
WO2006049681A2 (en) | 2004-08-30 | 2006-05-11 | Bayer Pharmaceuticals Corporation | Selective neuropeptide y2 receptor agonists |
US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
WO2007022123A2 (en) * | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
GB0504857D0 (en) | 2005-03-09 | 2005-04-13 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
CA2614619A1 (en) | 2005-07-11 | 2007-01-18 | Nastech Pharmaceutical Company Inc. | Formulations for enhanced mucosal delivery of pyy |
MX2007016024A (en) | 2005-07-18 | 2008-03-10 | Novo Nordisk As | Peptides for use in the treatment of obesity. |
US7851590B2 (en) | 2005-09-21 | 2010-12-14 | 7Tm Pharma A/S | Y2 selective receptor agonists for therapeutic interventions |
CA2623088A1 (en) | 2005-09-21 | 2007-04-12 | 7Tm Pharma A/S | Y4 selective receptor agonists for therapeutic interventions |
ES2381497T3 (en) | 2005-12-07 | 2012-05-28 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor agonists |
WO2007068718A1 (en) | 2005-12-14 | 2007-06-21 | Novo Nordisk A/S | Polypeptide protracting tags |
US20070197445A1 (en) | 2006-01-18 | 2007-08-23 | University Of Cincinnati | Compounds for control of appetite |
AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
GB0613196D0 (en) | 2006-07-03 | 2006-08-09 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
KR20140109509A (en) * | 2006-07-11 | 2014-09-15 | 큐피에스 엘엘씨 | Pharmaceutical compositions for sustained release delivery of peptides |
GB0621973D0 (en) | 2006-11-03 | 2006-12-13 | Philogen Spa | Binding molecules and uses thereof |
US20090099074A1 (en) | 2007-01-10 | 2009-04-16 | Conjuchem Biotechnologies Inc. | Modulating food intake |
JP2010516652A (en) | 2007-01-18 | 2010-05-20 | ノボ・ノルデイスク・エー/エス | Novel peptides used in the treatment of obesity |
US20100022446A1 (en) | 2007-01-18 | 2010-01-28 | Novo Nordisk A/S | Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity |
GB0708226D0 (en) | 2007-04-27 | 2007-06-06 | 7Tm Pharma As | Y-receptor agonists |
RU2506273C2 (en) | 2007-07-09 | 2014-02-10 | Импиэриэл Инноувейшнс Лимитид | Analogue of human pancreatic polypeptide (versions), pharmaceutical composition based thereon, method of treating obesity or diabetes, method of reducing appetite, reducing food intake or reducing calorie intake and method for cosmetic weight reduction using said analogue |
EP2190460B1 (en) | 2007-09-05 | 2014-12-17 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
US20100210559A1 (en) * | 2007-09-11 | 2010-08-19 | Mondobiotech Laboratories Ag | Trap-14 as a therapeutic agent |
US8598314B2 (en) | 2007-09-27 | 2013-12-03 | Amylin Pharmaceuticals, Llc | Peptide-peptidase-inhibitor conjugates and methods of making and using same |
KR20110017874A (en) * | 2008-05-16 | 2011-02-22 | 노보 노르디스크 에이/에스 | Long-acting y2 and/or y4 receptor agonists |
US8299023B2 (en) | 2008-09-17 | 2012-10-30 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists |
GB0817067D0 (en) | 2008-09-18 | 2008-10-22 | 7Tm Pharma As | Intestinal treatment |
JP2012507487A (en) | 2008-11-05 | 2012-03-29 | エフ.ホフマン−ラ ロシュ アーゲー | Neuropeptide 2 receptor (Y-2R) agonists and uses thereof |
CN102325545A (en) | 2009-02-20 | 2012-01-18 | 益普生制药股份有限公司 | Peptide-cytotoxic conjugates with neuropeptide Y receptor binding compounds |
CN102573888A (en) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | Long-acting Y2 receptor agonists |
WO2011045232A2 (en) | 2009-10-13 | 2011-04-21 | F. Hoffmann-La Roche Ag | Neuropeptide-2 receptor (y-2r) agonists |
WO2011058165A1 (en) * | 2009-11-13 | 2011-05-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
US9040660B2 (en) | 2010-04-20 | 2015-05-26 | Novo Nordisk A/S | Long-acting gastrin derivatives |
GB201101459D0 (en) | 2011-01-27 | 2011-03-16 | Imp Innovations Ltd | Novel compounds and thier effects on fedding behaviour |
EP2855517A1 (en) | 2012-05-29 | 2015-04-08 | Novo Nordisk A/S | Pancreatic polypeptide compounds and use |
AU2014261111B2 (en) | 2013-05-02 | 2017-03-16 | Glaxosmithkline Intellectual Property Development Limited | Therapeutic peptides |
WO2015071356A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Hpyy(1 -36) having a beta-homoarginine substitution at position 35 |
MX369818B (en) * | 2013-11-15 | 2019-11-22 | Novo Nordisk As | Selective pyy compounds and uses thereof. |
-
2016
- 2016-06-13 AU AU2016275735A patent/AU2016275735B2/en active Active
- 2016-06-13 TW TW105118511A patent/TWI694082B/en active
- 2016-06-13 KR KR1020177037622A patent/KR102476550B1/en active IP Right Grant
- 2016-06-13 CA CA2988500A patent/CA2988500A1/en not_active Withdrawn
- 2016-06-13 JP JP2017564450A patent/JP6731958B2/en active Active
- 2016-06-13 EP EP16734567.7A patent/EP3307768A1/en active Pending
- 2016-06-13 WO PCT/EP2016/063429 patent/WO2016198682A1/en active Application Filing
- 2016-06-13 RU RU2017145348A patent/RU2726777C2/en active
- 2016-06-13 AR ARP160101755A patent/AR104984A1/en unknown
- 2016-06-13 MA MA043205A patent/MA43205A/en unknown
- 2016-06-13 BR BR112017025108A patent/BR112017025108A2/en active Search and Examination
- 2016-06-13 MX MX2017015105A patent/MX2017015105A/en unknown
- 2016-06-13 CN CN201680045277.3A patent/CN107849110B/en active Active
- 2016-06-13 MY MYPI2017704318A patent/MY187047A/en unknown
-
2017
- 2017-06-28 US US15/635,456 patent/US10005824B2/en active Active
- 2017-11-16 ZA ZA2017/07782A patent/ZA201707782B/en unknown
- 2017-11-20 IL IL255781A patent/IL255781B/en unknown
- 2017-11-30 SA SA517390445A patent/SA517390445B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
MA43205A (en) | 2018-09-19 |
TWI694082B (en) | 2020-05-21 |
CN107849110B (en) | 2021-11-26 |
MY187047A (en) | 2021-08-27 |
EP3307768A1 (en) | 2018-04-18 |
CA2988500A1 (en) | 2016-12-15 |
ZA201707782B (en) | 2019-08-28 |
RU2726777C2 (en) | 2020-07-15 |
IL255781B (en) | 2021-10-31 |
AU2016275735B2 (en) | 2020-02-06 |
CN107849110A (en) | 2018-03-27 |
US10005824B2 (en) | 2018-06-26 |
TW201710284A (en) | 2017-03-16 |
IL255781A (en) | 2018-04-30 |
KR20180019616A (en) | 2018-02-26 |
KR102476550B1 (en) | 2022-12-13 |
MX2017015105A (en) | 2018-05-07 |
AU2016275735A1 (en) | 2017-12-07 |
BR112017025108A2 (en) | 2018-07-31 |
RU2017145348A (en) | 2019-07-12 |
US20170313750A1 (en) | 2017-11-02 |
WO2016198682A1 (en) | 2016-12-15 |
SA517390445B1 (en) | 2020-12-21 |
JP2018522843A (en) | 2018-08-16 |
JP6731958B2 (en) | 2020-07-29 |
RU2017145348A3 (en) | 2019-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR104984A1 (en) | SELECTIVE COMPOUNDS FOR PYY AND ITS USES | |
CL2018003681A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
SV2015005115A (en) | DERIVATIVES OF PIRAZOLOPIRROLIDINE AND ITS USE IN THE TREATMENT OF DISEASES | |
BR112016010383A2 (en) | selective pyy compounds and uses thereof | |
PE20191474A1 (en) | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
NI201700011A (en) | 2- (MORFOLIN-4-IL) -1,7-NAPHTHYRIDINES. | |
UY39706A (en) | DERIVATIVES OF (1HINDOL-3-IL)-2-(4-CHLORO-2-METHOXY-PHENYL)-2-((3-METHOXY-5-(METHYLSULFONYL) PHENYL)AMINO)ETHANONE AS INHIBITORS OF THE REPLICATION OF THE VIRUS OF THE DENGUE | |
CL2015002608A1 (en) | Amino-pyrazole compound and related medicinal uses. | |
SV2018005687A (en) | DIHYDROIMIDAZOPIRAZINONA DERIVATIVES USED IN CANCER TREATMENT | |
UY37645A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
GT201600269A (en) | DERIVATIVES OF INDANO AND INDOLINA AND THE USE OF THE SAME AS ACTIVATORS OF THE SOLUBLE CYCLING GUANILATE | |
GT201700023A (en) | OPTIONALLY CONDENSED HYDERO-CYCLIC DERIVATIVES OF PIRIDIMINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGICAL AND AUTOINMUNITY DISEASES | |
UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
CL2016001973A1 (en) | Nucleoside derivatives substituted with 4'-difluoromethyl as inhibitors of influenza arn replication. | |
UY37742A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
CL2016001918A1 (en) | Heteroaryl amides as protein aggregation inhibitors | |
CL2019001991A1 (en) | Estrogen receptor modulators. | |
UY36124A (en) | CARBOXAMIDE DERIVATIVES | |
AR096338A1 (en) | (CIANO-DIMETHYL-METHYL) -ISOXAZOLS AND - [1,3,4] TIADIAZOLES | |
ECSP16086247A (en) | (S) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE | |
DOP2019000100A (en) | DERIVATIVES OF NAFTIRIDINONE AND ITS USE IN THE TREATMENT OF ARRITMIA | |
PE20150167A1 (en) | (R) -NIFURATEL, ITS USE FOR THE TREATMENT OF INFECTIONS AND SYNTHESIS OF (R) AND (S) -NIFURATEL | |
CR20160529A (en) | PHARMACEUTICAL COMPOSITIONS TO TREAT INFECTIOUS DISEASES | |
CL2016000884A1 (en) | Piperazine derivatives and their use as a medicine. | |
ECSP16086232A (en) | (R) -PIRLINDOLE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS FOR USE IN MEDICINE |